What condition is Carvedilol indicated for according to its FDA label?

Carvedilol is indicated for heart failure with reduced ejection fraction according to its FDA label. This medication is a non-selective beta-blocker that also possesses alpha-1 blocking activity, making it particularly effective in treating heart failure. It helps in improving cardiac output, reducing the heart's workload, and managing symptoms associated with heart failure.

Heart failure with reduced ejection fraction means the heart is not pumping blood as effectively as it should, and Carvedilol assists in improving the heart's functionality, thereby reducing hospitalizations and improving patient survival. This indication is supported by clinical studies that demonstrated its safety and efficacy in this specific patient population.

Other conditions listed, such as hypotension, arrhythmias, and hyperlipidemia, are not primary indications for Carvedilol. While beta-blockers can sometimes be used for managing arrhythmias, Carvedilol's primary FDA-approved use focuses specifically on heart failure. The other conditions are either managed through other classes of medications or are not indicated for Carvedilol's use.